Pyrazolopyrimidine compounds for the treatment of cancer
Compounds of Formula I are described, along with pharmaceutically acceptable salts thereof, compositions containing the same, and methods of use thereof.
1. A compound selected from the following:
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein said compound is:
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 , wherein said compound is:
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 , wherein said compound is:
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1 , wherein said compound is:
or a pharmaceutically acceptable salt thereof.
6. The compound of claim 1 , wherein said compound is:
or a pharmaceutically acceptable salt thereof.
7. A pharmaceutical composition comprising a compound of claim 1 in a pharmaceutically acceptable carrier.
8. A method of treating cancer in a subject in need thereof, comprising administering to said subject a compound of claim 1 in an amount effective to treat said cancer, wherein said cancer is selected from the group consisting of myeloid leukemia, lymphoblastic leukemia, melanoma, breast, lung, colon, liver, gastric, kidney, ovarian, uterine, and brain cancer.
9. A method of inhibiting blood clot formation in a subject in need thereof, comprising administering to said subject the compound of claim 1 in an amount effective to inhibit blood clot formation.